Simvastatin therapy in climacteric women with atherogenic dyslipoproteinemias
The study aimed to assess real-world clinical practice effectiveness and safety of simvastatin therapy in climacteric women. A prospective cohort study included 82post-menopausal women with lipid-lowering therapy indications; median age 56,5 (52,0-60,0) years. Simvastatin therapy lasted for one year...
Main Authors: | N. V. Izmozherova, A. A. Popov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2008-04-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1540 |
Similar Items
-
Cardiovascular disease prevalence in climacteric women with carbohydrate metabolism disorders
by: N. V. N.V. Izmozherova, et al.
Published: (2008-02-01) -
Cardiovascular disease prevalence in climacteric women with manifested knee osteoarthrosis
by: N. V. Izmozherova, et al.
Published: (2006-10-01) -
Cardiovascular risk factors in climacteric women with hyperuricemia
by: N. V. Tagiltseva, et al.
Published: (2007-08-01) -
Arterial hypertension and comorbidity prevalence in climacteric women
by: N. V. Izmozherova, et al.
Published: (2008-04-01) -
Cardiovascular system status in women with severe climacteric syndrome
by: N. V. Izmozherova, et al.
Published: (2007-02-01)